reports
- Matt Borsch
DuraGraft Approved for US Markets
Key milestone in FDA approval. On October 6, Marizyme, Inc. (MRZM) announced a key milestone in its growth strategy, with FDA approval of its flagship DuraGraft (DG) technology for the US market. Improved outcomes when used in cardiac care. DG has been proven to result in significantly improved outcomes and lower costs for cardiac surgery through multiple clinical trials as well as utilization in selected markets in Europe and Asia where adoption has recently accelerated. Reflecting that, YTD DG...
- Matt Borsch
Water Tower Hour Recap: Powerful Technology Platform Driving Strong Gr...
Marizyme, Inc. (MRZM) is a fast-growing biomedical company with a powerful multi-technology platform. At the forefront is DuraGraft (DG), which has already demonstrated improved outcomes and lower costs for cardiac care through clinical trials and actual implementation in select overseas markets. In addition to continued ‘OUS’ expansion, MRZM is readying for the implementation of DG in US markets, pending FDA approval. CEO and Director David Barthel joined us on The Water Tower Hour podcast to p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.